Introduction
Thionamide antithyroid drugs are the established initial treatment for patients with Graves' disease in Europe (1) . Some clinicians prefer single treatment, others combine these drugs with thyroxine (2) (3) (4) (5) . The primary intention of the combined therapy is to avoid druginduced hypothyroidism during antithyroid treatment. However, it has been suggested that the continuous administration of thyroxine (T4) and the associated decrease in thyrotropin (TSH) serum concentrations might have additional beneficial effects on the course of Graves' disease. Thus, Japanese patients who received T4 therapy during antithyroid drug treatment and the subsequent year had a strikingly lower relapse rate of hyperthyroidism than patients treated with thionamide drugs alone (6) . In (Fig. 3) .
In eight patients with an initial goiter who remained in remission, we had the chance to repeat sonographic measurements one year after the end of our study. Despite the fact that they had discontinued T4 therapy for one year by this time, all four patients on former TSH suppressive treatment had maintained a normal thyroid volume (14-1 ±4-5 ml) and had experienced no increase in thyroid volume since discontinuation of the T4 treatment (-3 ± 3-9 ml). In contrast, in the four patients on nonsuppressive treatment, thyroid volume had remained enlarged (37-3 ± 16-3ml; = 0-025 compared with suppressive treatment) and was unchanged compared with one year after cessation of the carbimazole therapy (-0-6 ± 8-5 ml).
Discussion
Frompted by the findings of Hashizume et al. (6) 
